Molecular diagnostics firm Sense Biodetection has announced a new partnership with R-Biopharm. for the non-exclusive distribution in the Netherlands, Belgium, and Luxembourg of Sense’s Veros instrument-free, point-of-care molecular testing platform.
Veros is the first and only self-contained, single-use COVID-19 diagnostic that produces highly accurate molecular results in approximately 15 minutes, unconstrained by a reader or need for external power.
R-Biopharm is a leading specialty medical distributor with proven success in creating value by connecting innovative manufacturers with customers in the Benelux Union. The agreement with R-Biopharm Nederland B.V. is the latest partnership for Sense as it continues to expand commercialisation of Veros COVID-19.
Sense Chief Commercial Officer Ryan Roberts said: “R-Biopharm is an exceptionally strong distribution partner who will provide great representation for Sense’s best-in-class technologies in the Benelux region. As winter approaches in the northern hemisphere, there is already evidence of increasing COVID-19 cases and new emergent variants. It is essential for health-care providers to have access to the most cutting-edge technologies so that they are able to care for their patients with complete knowledge of their COVID status. We believe Veros COVID-19’s instrument-free design, and its rapid, molecular assay, which delivers a result in about 15 minutes, meets the criteria.”
Using a proprietary rapid molecular amplification technology, Veros aims to provide point-of-care testing for many more people and help reduce the spread of COVID-19 with faster, accurate, more accessible diagnoses. Veros COVID-19’s clinical performance was established in a comprehensive, multicenter, prospective clinical trial, enrolling nearly 300 consecutive, evaluable subjects during both the Delta and Omicron variant surges of the pandemic. All study sites represented near-patient testing / point-of-care environments, with all test operators reporting no prior formal laboratory training or experience. 100% of operators agreed the Veros COVID-19 was easy-to-use, read, and understand the results, with minimal hands-on time required from start to finish.
As the virus continues to evolve, Veros COVID-19 has maintained the ability to detect all variants identified to date by WHO and the US CDC, including all Omicron sub-variants.
